New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand

NEW YORK, July 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Elan Corporation, plc (ADR) (NYSE: ELN), Waters Corporation (NYSE: WAT), InterMune Inc. (NASDAQ: ITMN), The Spectranetics Corporation (NASDAQ: SPNC), and Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Elan Corporation, plc (ADR) Research Report

On July 24, 2013, Elan Corporation (Elan) reported its Q2 2013 financial results. Total revenues from continuing operations were $56.3 million compared to an expense of $0.2 million in Q2 2012. Net income for Q2 2013 was approximately $2.3 billion or $4.28 per diluted share, compared to net loss of $28.5 million or $0.05 per diluted share in Q2 2012. Elan's CFO Nigel Clerkin said, "Our second quarter results have been substantially impacted by the completion of the Tysabri transaction, the subsequent $1.0 billion share buyback, debt retirements and other transactions. Our net income for the quarter, of $2,288.7 million, reflects the gain recorded on the Tysabri transaction of $2,540.2 million, while our sharecount was reduced by approximately 15%. We remain in a very strong financial position, and ended the quarter with over $1.9 billion in cash and cash equivalents, and no debt.^["] The Full Research Report on Elan Corporation, plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e996_ELN]

--

Waters Corporation Research Report

On July 23, 2013, Waters Corporation reported its financial results for Q2 FY 2013 (period ended June 29, 2013). Net sales decreased 0.1% YoY to $451.1 million. Net income stood $89.3 million or $1.03 per diluted share in Q2 FY 2013 compared to net income of $97.7 million or $1.09 per diluted share in Q2 FY 2012. Commenting on the news, Douglas Berthiaume, Chairman, President and CEO of Waters, said, "A late-quarter unexpected slowdown in instrument system orders offset strong recurring revenue growth and contributed to an overall disappointing performance in the second quarter. We believe that underlying demand for instrument systems is, in fact, stronger than indicated by our weak sales growth in the quarter, as order delays and a meaningful backlog build combined in late June to negatively affect our sales and earnings." The Full Research Report on Waters Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2fff_WAT]

--

InterMune Inc. Research Report

On July 24, 2013, InterMune Inc. (InterMune) reported its Q2 2013 financial results and the Company's recent business highlights. The Company stated that Esbriet (pirfenidone) revenue was up 161.8% YoY to $14.4 million. Net loss for Q2 2013 was $62.9 million or $0.77 per diluted share compared with a net loss of $9.3 million or $0.14 per diluted share in Q2 2012. Commenting on the results, Dan Welch, Chairman, CEO, and President of InterMune, said, "We continue to successfully execute on our EU and Canadian growth strategy and are pleased to report the seventh consecutive quarter of revenue growth of Esbriet since its first launch in Germany in September 2011. Having recently secured attractive pricing and reimbursement in Italy, England and Ireland, Esbriet is now priced and reimbursed in 13 of our original 15 top-priority European countries, a solid achievement when considering the challenging economic conditions in the EU." The Company expects full-year 2013 revenue from its product Esbriet to be within $55 million to $70 million. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/dd8c_ITMN]

--

The Spectranetics Corporation Research Report

On July 24, 2013, The Spectranetics Corporation (Spectranetics) reported its Q2 2013 financial results. Total revenue increased 12.6% YoY to $39.5 million. Net loss was approximately $0.7 million or $0.02 per diluted share in Q2 2013, compared to net income of approximately $0.6million or $0.02 per diluted share in Q2 2012. According to the Company vascular intervention revenue, lead management revenue and laser system and other revenue increased by 8% YoY, 11% YoY and 34% YoY to $18.9 million, $15.1 million and $5.5 million respectively. Spectranetics President and CEO Scott Drake said, "We placed 48 lasers this quarter, surpassing our previous record from the fourth quarter 2012 of 42 laser placements, which bodes well for future revenue growth. Our long term objective is unchanged - accelerating revenue growth and gross margin expansion yielding meaningful operating leverage over time." The Full Research Report on The Spectranetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/82e6_SPNC]

--

Ligand Pharmaceuticals Inc. Research Report

On July 24, 2013, Ligand Pharmaceuticals Inc. (Ligand) announced that it has signed a license agreement with Ethicor Pharma Ltd. (Ethicor) for the manufacturing and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland, and Indian Subcontinent. According to the agreement, Ligand is entitled to receive potential sales milestones and a double digit royalty on future net sales. The Company informed that lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases that was discovered through the research and collaboration between Ligand and Pfizer that began in 1991. Ligand said that Ethicor plans to supply oral lasofoxifene as an unlicensed medicinal product, which may be requested by healthcare professionals to meet the clinical needs of patients when authorized medicines are unsuitable or contraindicated. The Full Research Report on Ligand Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3b8d_LGND]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner